Oxaliplatin

Manufactured by Bio-Techne

Sourced in United Kingdom, United States

Oxaliplatin is a platinum-based anti-cancer drug used in the treatment of colorectal cancer. It functions as a DNA-damaging agent, inhibiting DNA synthesis and cell division.

Automatically generated - may contain errors

Lab products found in correlation

Sulforhodamine b colorimetric assay, by Merck Group (2 mentions) 5 fluorouracil, by Bio-Techne (2 mentions) Cisplatin, by Merck Group (2 mentions) Doxorubicin, by Merck Group (2 mentions) Dimethyl sulfoxide (dmso), by Merck Group (2 mentions) Penicillin, by Thermo Fisher Scientific (1 mentions) Streptomycin, by Thermo Fisher Scientific (1 mentions) Ham s f 12k, by Thermo Fisher Scientific (1 mentions) Fetal bovine serum (fbs), by Thermo Fisher Scientific (1 mentions) Etoposide, by Selleck Chemicals (1 mentions) Doxorubicin, by Selleck Chemicals (1 mentions) Ly2603618, by Selleck Chemicals (1 mentions) Mk 8776, by Chemietek (1 mentions) 5 fluorouracil, by Merck Group (1 mentions) Camptothecin, by LC Laboratories (1 mentions) Fsllry nh2, by Bio-Techne (1 mentions) Hc 030031, by Merck Group (1 mentions) Sn 38, by Bio-Techne (1 mentions) Methyl thiazolyl tetrazolium (mtt), by Merck Group (1 mentions) Gemcitabine, by Bio-Techne (1 mentions)

25 protocols using oxaliplatin

Oxaliplatin-Induced Neuropathic Pain Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

For the oxaliplatin-induced neuropathic
pain assay, oxaliplatin (Tocris) was dissolved in water with gentle
warming and was subcutaneously (sc) injected on days 1, 3, and 5 at
a 6 mg/kg dose. The day 7 after administration, experiments were performed.
Together with oxaliplatin injection, saline and a 5% mannitol solution
were intraperitoneally injected to prevent kidney damage and dehydration. 31a stock was prepared in DMSO (Sigma-Aldrich) and diluted
in saline for injections. Compound 31a at different doses
(1 to 30 μg) was injected into the plantar surface (25 μL)
of the right hind paw of mice.
For the other in vivo assays,
compound 4 and 31a were dissolved in PEG
400 10% v/v, Tween 80 5% v/v, and sterile saline 85% v/v and injected
once intraperitoneally at the equimolar doses of 10 mg/kg for 4 and 6.7 mg/kg for 31a. Control group was only
treated with vehicle.

Bertamino A., Ostacolo C., Medina A., Di Sarno V., Lauro G., Ciaglia T., Vestuto V., Pepe G., Basilicata M.G., Musella S., Smaldone G., Cristiano C., Gonzalez-Rodriguez S., Fernandez-Carvajal A., Bifulco G., Campiglia P., Gomez-Monterrey I, & Russo R. (2020). Exploration of TRPM8 Binding Sites by β-Carboline-Based Antagonists and Their In Vitro Characterization and In Vivo Analgesic Activities. Journal of Medicinal Chemistry, 63(17), 9672-9694.

+ Open protocol

+ Expand

Oxaliplatin-Induced Colon Injury in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mice received intraperitoneal (i.p.) injections of oxaliplatin (Tocris Bioscience, UK) 3 mg/kg/dose 3 times a week with a 26 gauge needle for 2 weeks as previously reported [8] .
oxaliplatin was dissolved in sterile water in order to make 10 -2 M stock solutions and refrigerated at -20 °C. The stock was then defrosted and diluted further to make 10 -3 mM solutions for intraperitoneal injections. The dose of oxaliplatin was calculated to be equivalent to standard human dose per body surface area [34, 35] . Vehicle-treated mice received sterile water via i.p. injections 3 times a week with a 26 gauge needle. Maximum volume did not exceed 200 µL per injection. Mice were euthanized via cervical dislocation 14 days after the first oxaliplatin injection and colon tissues were collected for in vitro experiments.

Donald E.L., Stojanovska L., Apostolopoulos V, & Nurgali K. (2017). Resveratrol alleviates oxidative damage in enteric neurons and associated gastrointestinal dysfunction caused by chemotherapeutic agent oxaliplatin. Maturitas, 105.

+ Open protocol

+ Expand

Cytotoxicity and Migration Assays for Cancer Cells

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cell migration and wound-healing assays were carried out as previously outlined^{5 (link)}. For the cytotoxicity assay, cells were serum-starved for 18 h and then treated with 5-FU or Oxaliplatin (Tocris) for 72 h, and sulforhodamine-B colorimetric assay (Sigma, 230162) was performed as previously described^{24 ,31 (link)}. HCT116^{FBXW7(−/−)} and HCT116^FBXW7(+/+) cell lines with or without ZEB2-shRNA were resistant to 5-FU generated by repeated exposure to increasing concentrations of 5-FU over 2–3 months^{59 (link)}.

Li N., Babaei-Jadidi R., Lorenzi F., Spencer-Dene B., Clarke P., Domingo E., Tulchinsky E., Vries R.G., Kerr D., Pan Y., He Y., Bates D.O., Tomlinson I., Clevers H, & Nateri A.S. (2019). An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistance. Oncogenesis, 8(3), 13.

+ Open protocol

+ Expand

FOLFOX Dose-Response Assay for Gastric Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols

Our combination FOLFOX (5-fluorouracil, oxaliplatin, and leucovorin) dose–response assay was validated using the human gastric cancer cell line AGS (ATCC CRL-1739). AGS cells were cultured in Ham’s F-12K (Gibco), 10% FBS (Gibco), 100 units/mL penicillin, and 100 µg/mL streptomycin (Gibco). Briefly, 5000 cells were plated in 96-well plates and grown for 24 h. Anti-cancer drugs 5-fluorouracil (Tocris, 3257) and oxaliplatin (Tocris, 2623) were added in triplicate over 8 half-log dilutions with 800 µM and 2400 µM initial concentrations, respectively. A single 500 µM dose of Leucovorin (Toronto Research, L330400) was added to each treatment well. Cells were treated for 48 h, followed by a CCK-8 viability assay (Abcam, ab228554), which was performed according to the manufacturer’s protocol. We replicated our assay in three independent trials to assess reproducibility.
For organoid dose–response assays, organoids were passaged and dissociated according to our protocol. As above, 5000 cells were plated in 96-well plates and grown in organoid media for 24 h, followed by 48 h of FOLFOX treatment and viability assessment using a CCK-8 assay.

Skubleny D., Garg S., Wickware J., Purich K., Ghosh S., Spratlin J., Schiller D.E, & Rayat G.R. (2023). Murine and Human Gastric Tissue Establishes Organoids after 48 Hours of Cold Ischemia Time during Shipment. Biomedicines, 11(1), 151.

+ Open protocol

+ Expand

Preparation of Anticancer Drug Stocks

Check if the same lab product or an alternative is used in the 5 most similar protocols

Solid stocks were purchased from the indicated suppliers and prepared as concentrated stock solutions in the appropriate solvent: gemcitabine (Apin Chemicals Inc), 20 mM in H₂O; camptothecin (LC Laboratories), 5 mM in DMSO; cisplatin (David Bull Laboratories), 3.33 mM in 1% NaCl in H₂O; oxaliplatin (Tocris), 5 mM in H₂O; etoposide (Selleckchem), 20 mM in DMSO; doxorubicin (Selleckchem), 5 mM in DMSO; 5-fluorouracil (Sigma), 50 mM in DMSO; LY2603618 (Selleckchem), 20 mM in DMSO and MK-8776 (ChemieTek), 20 mM in DMSO.

Rawlinson R, & Massey A.J. (2014). γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments. BMC Cancer, 14, 483.

+ Open protocol

+ Expand

Rat Model of Oxaliplatin-Induced Neuropathy

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Oxaliplatin (Tocris Bioscience, R&D Systems, Minneapolis, MN, USA) was dissolved in a 5% glucose solution at a final concentration of 2 mg/ml. Acute neurotoxicity was induced in rats by a single intraperitoneal (i.p.) injection of Oxaliplatin (6 mg/kg), as described previously [7 (link), 8 (link)]. Control rats received the same volume of i.p. injection of vehicle. Mechanical allodynia and cold hypersensitivity were fully developed by OXL 3 days after injection.
PAR2 antagonist FSLLRY-NH2 (Tocris Bioscience, R&D Systems, Minneapolis, MN, USA) and TRPA1 antagonist HC030031 (Sigma-Aldrich, St. Louis, MO, USA) were injected i.p. and then mechanical and cold sensitivity were determined within 8 hrs after the drugs administration. The separated animals were used for experiments of the dosage response in each group.

Tian L., Fan T., Zhou N., Guo H, & Zhang W. (2015). Role of PAR2 in regulating oxaliplatin-induced neuropathic pain via TRPA1. Translational Neuroscience, 6(1), 111-116.

+ Open protocol

+ Expand

Cytotoxicity Assay for Cell Lines

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Same passage number of HCT116, DLD-1 and SW480 cells were seeded in 96-well plate and were allowed to grow. Subsequently, cells were serum-starved for 18 h and then were treated with a drug by itself or with 5-FU and Oxaliplatin (Tocris, Abingdon, UK) for 72 h. Sulforhodamine-B colorimetric assay (230162, Sigma Aldrich, Gillingham, UK) was performed as previously described [33 (link)].

Ahmed M., Jinks N., Babaei-Jadidi R., Kashfi H., Castellanos-Uribe M., T. May S., Mukherjee A, & Nateri A.S. (2019). Repurposing Antibacterial AM404 As a Potential Anticancer Drug for Targeting Colorectal Cancer Stem-Like Cells. Cancers, 12(1), 106.

+ Open protocol

+ Expand

Viability Assay for Chemotherapeutic Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols

For viability assays, cells were treated with doxycycline to induce shRNA expression for 4 days and then seeded at a density of 4000 cells/well in a 96-well plate in doxycycline containing media. 24 hours post plating, either SN-38 (Tocris Biosciences), or oxaliplatin (Tocris Biosciences), or vehicle was added. Following a 72h treatment, cell viability was assessed by the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide; Sigma-Aldrich) assay according to the manufacturer’s protocol. Viable fraction is expressed as the percentage of vehicle treated control cells. EC50 was calculated using Graphpad Prism v4.0 software.

Grabocka E., Pylayeva-Gupta Y., Jones M.J., Lubkov V., Yemanaberhan E., Taylor L., Jeng H.H, & Bar-Sagi D. (2014). Wild-type H- and N-Ras promote mutant K-Ras driven tumorigenesis by modulating the DNA damage response. Cancer cell, 25(2), 243-256.

+ Open protocol

+ Expand

Chemoresistant Cell Line Generation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Increasing concentrations of oxaliplatin and/or gemcitabine (Tocris; Bristol, UK) were added to each cell type in regular media over the course of approximately 25 passages until a stable proliferative phenotype without chemotherapy was observed and maintained following cryopreservation and thawing. Drug resistance was confirmed by comparative dose response and measurement of a statistically significant increase in IC50.

Cramer G.M., Jones D.P., El Hamidi H, & Celli J.P. (2016). ECM Composition and Rheology Regulate Growth, Motility and Response to Photodynamic Therapy in 3D Models of Pancreatic Ductal Adenocarcinoma. Molecular cancer research : MCR, 15(1), 15-25.

+ Open protocol

+ Expand

Acute Oxaliplatin-Induced Neuropathic Pain

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Oxaliplatin was purchased from Tocris Bioscience (United Kingdom) and freshly dissolved in 5% glucose solution. For the acute Oxaliplatin model, mice received a single intraperitoneal administration of Oxaliplatin (6 mg/kg) or vehicle.^{4 (link)} Tramadol hydrochloride (5 mg/kg, Sigma, Belgium) was prepared in a mixture of 1% hydroxypropylmethylcellulose HPMC/0.5% Tween 80 and administered through oral gavage. Isosakuranetin (2 mg/kg) was dissolved in Miglyol 812 (Caesar & Loretz GmbH, Hilden, Germany) containing 0.1% dimethyl sulfoxide (DMSO), and compounds or the vehicle alone were injected intraperitoneally. Primidone and PS were purchased from Sigma-Aldrich (Belgium) and dissolved in DMSO. Stock solutions were 20 mM and 100 mM, respectively.

Aloi V.D., Pinto S.J., Van Bree R., Luyten K., Voets T, & Vriens J. (2023). TRPM3 as a novel target to alleviate acute oxaliplatin-induced peripheral neuropathic pain. Pain, 164(9), 2060-2069.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!